Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.

ABSTRACT:

SUBMITTER: Kitzmuller C 

PROVIDER: S-EPMC6767596 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature